Board Member
TerrAscend Corp. (TSNDF)Chief Accounting Officer
Heron Therapeutics, Inc. (HRTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Heron Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRTX alertsIra Duarte is recorded as Chief Accounting Officer at Heron Therapeutics, Inc. (HRTX) since March 29, 2024, CFO at Heron Therapeutics, Inc. (HRTX) and Board Member at TerrAscend Corp. (TSNDF) since June 9, 2026. The newest filing on record that lists Ira Duarte as CFO at Heron Therapeutics, Inc. (HRTX) is dated April 30, 2026. TerrAscend Corp. reported in an 8-K filed June 15, 2026 that Ira Duarte was appointed Director, effective June 9, 2026. TerrAscend Corp. reported in an 8-K filed June 24, 2025 that Ira Duarte was appointed Director, effective June 24, 2025. Heron Therapeutics, Inc. reported in an 8-K filed March 21, 2024 that Ira Duarte was appointed principal accounting officer, effective March 29, 2024. Equibles holds 6 filed executive changes naming Ira Duarte; each is listed under recent activity with its source filing. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $1,630,678 for Ira Duarte in fiscal 2025, including a base salary of $559,803. Disclosed compensation is on record for 4 fiscal years. Ira Duarte has spoken on 13 earnings calls across 1 company, most recently for Heron Therapeutics, Inc. on August 10, 2026. Heron Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. TerrAscend Corp. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Heron Therapeutics, Inc. includes Craig Collard (CEO and Board Member), Adam Morgan (Chairman and Board Member), Mark Hensley (COO) and 7 others.
“Each of the five individuals listed below was elected at the Annual Meeting to serve on the Company’s Board of Directors (the "Board") until the close of the next annual meeting of shareholders of the Company following his or her election, or any postponement(s) or adjournment(s) thereof, unless his or her office is vacated earlier or until his or her successor is elected or appointed.”
“Each of the five individuals listed below was elected at the Annual Meeting to serve on the Company's Board of Directors (the "Board") until the close of the next annual meeting of shareholders of the Company following his or her election, or any postponement(s) or adjournment(s) thereof, unless his or her office is vacated earlier or until his or her successor is elected or appointed.”
“Craig has addressed the quarter directly. What is within our control is how we manage the business in response, and disciplined management of our balance sheet and our spending is what is important moving forward.”
“As Craig noted, our financial results this quarter came in modestly below plan. That said, while winter storms are outside of our control, how we manage our business in response to them is not.”
“Our financial performance in 2025 underscores the meaningful progress Heron continues to make in transforming its commercial trajectory while maintaining strong financial discipline.”
“Our product gross profit for the three months ended September 30, 2025, was $26.3 million or 68.8%, which decreased from 71.2% for the same period in 2024.”
“Yes, the pro forma common share is about 183 million shares, and pro forma shares, including the convert, would be about 208 million.”
2026-06-09–present
2024-03-29–present
SEC 8-K
2022-12-01–present
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2024-03-29–present
TSNDF
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2022-12-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Financial Officer | $559,803 | $1,630,678 |
| 2024 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Financial Officer | $592,250 | $1,536,130 |
| 2023 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Financial Officer | $271,154 | $1,534,873 |
| 2022 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Financial Officer | — | — |
